Methotrexate is an effective and safe adjuvant therapy for pemphigus vulgaris

European Journal of Dermatology

Volumn 22, Issue 1, 2012, Pages 83-87

  Baum, Sharon ^a   Greenberger, Shoshana ^a   Samuelov, Liat ^b   Solomon, Michal ^a   Lyakhovitsky, Anna ^a   Trau, Henri ^a   Barzilai, Aviv ^a  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Methotrexate; Pemphigus vulgaris; Steroid sparing treatment

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DAPSONE; IMMUNOGLOBULIN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ADJUVANT THERAPY; ADULT; AGED; ALOPECIA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; LOW DRUG DOSE; MALE; PEMPHIGUS VULGARIS; RETROSPECTIVE STUDY; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; METHOTREXATE; MIDDLE AGED; PEMPHIGUS; PREDNISONE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; YOUNG ADULT;

EID: 84857842620     PISSN: 11671122     EISSN: 19524013     Source Type: Journal    
DOI: 10.1684/ejd.2011.1611     Document Type: Article

References (29)

1. Scott JE, Ahmed AR. The blistering diseases. Med Clin North Am 1998; 82: 1239-83.
2. Leuci S, Levine D, Zhang J et al. Response in patients with pemphigus vulgaris to rituximab therapy. Basis of the biology of B cells. G Ital Dermatol Venereol 2009; 144: 379-409.
3. Carson PJ, Hameed A, Ahmed AR. Influence of treatment on the clinical course of pemphigus vulgaris. J Am Acad Dermatol 1996; 34: 645-52.
4. Martin LK, Werth VP, Villaneuva EV et al. A systematic review of randomized controlled trials for pemphigus vulgaris and pemphigus foliaceus. J Am Acad Dermatol; 64: 903-8.
5. Gurcan HM, Ahmed AR. Analysis of current data on the use of methotrexate in the treatment of pemphigus and pemphigoid. Br J Dermatol 2009;161:723-31.
6. Langan SM, Smeeth L, Hubbard R et al. Bullous pemphigoid and pemphigus vulgaris-incidence and mortality in the UK: population based cohort study. Bmj 2008; 337: a180.
7. Lever WF. Methotrexate and prednisone in pemphigus vulgaris. Therapeutic results obtained in 36 patients between 1961 and 1970. Arch Dermatol 1972; 106: 491-7.
8. Lever WF, Goldberg HS. Treatment of pemphigus vulgaris with methotrexate. Arch Dermatol 1969; 100: 70-8.
9. Lever WF, Schaumburg-Lever G. Immunosuppressants and prednisone in pemphigus vulgaris: therapeutic results obtained in 63 patients between 1961 and 1975. Arch Dermatol 1977; 113:1236-41.
10. Peck SM, Osserman KE, Samuels AJ et al. Studies in bullous diseases. Treatment of pemphigus vulgaris with immunosuppressives (steroids and methotrexate) and leucovorin calcium. Arch Dermatol 1971; 103: 141-7.
11. Smith TJ, Bystryn JC. Methotrexate as an adjuvant treatment for pemphigus vulgaris. Arch Dermatol 1999; 135: 1275-6.
12. Bangert CA, Costner MI. Methotrexate in dermatology. Dermatol Ther 2007;20:216-28.
13. Bogas M, Machado P, Mourao AF et al. Methotrexate treatment in rheumatoid arthritis: management in clinical remission, common infection and tuberculosis. Results from a systematic literature review. Clin Rheumatol.
14. Burrows D, Shanks RG, Stevenson CJ. Methotrexate in dermatology. Br J Dermatol 1968; 80: 348-52.
15. Goujon C, Berard F, Dahel K et al. Methotrexate for the treatment of adult atopic dermatitis. Eur J Dermatol 2006; 16: 155-8.
16. Weatherhead SC, Wahie S, Reynolds NJ et al. An open-label, dose-ranging study of methotrexate for moderate-to-severe adult atopic eczema. Br J Dermatol 2007; 156: 346-51.
17. Cronstein BN. Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev 2005; 57: 163-72.
18. Genestier L, Paillot R, Quemeneur L et al. Mechanisms of action of methotrexate. Immunopharmacology 2000; 47: 247-57.
19. Egan CA, Rallis TM, Meadows KP et al. Low-dose oral methotre-xate treatment for recalcitrant palmoplantar pompholyx. J Am Acad Dermatol 1999; 40: 612-4.
20. Zoller L, Ramon M, Bergman R. Low dose methotrexate therapy is effective in late-onset atopic dermatitis and idiopathic eczema. Isr Med Assoc J 2008; 10: 413-4.
21. Jablonska S, Chorzelski T, Blaszczyk M. Immunosuppressants in the treatment of pemphigus. Br J Dermatol 1970; 83: 315-23.
22. Mashkilleyson N, Mashkilleyson AL. Mucous membrane manifestations of pemphigus vulgaris. A 25-year survey of 185 patients treated with corticosteroids or with combination of corticosteroids with methotrexate or heparin. Acta Derm Venereol 1988; 68: 413-21.
23. Piamphongsant T, Sivayathorn A. Pemphigus: combined treatment with methotrexate and prednisone. J Med Assoc Thai 1975; 58: 171-6.
24. Ryan JG. Pemphigus. A 20-year survey of experience with 70 cases. Arch Dermatol 1971; 104: 14-20.
25. Baskan EB, Yilmaz M, Tunali S et al. Efficacy and safety of long-term mycophenolate sodium therapy in pemphigus vulgaris. J Eur Acad Dermatol Venereol 2009; 23: 1432-4.
26. El Tal AK, Posner MR, Spigelman Z et al. Rituximab: a monoclonal antibody to CD20 used in the treatment of pemphigus vulgaris. J Am Acad Dermatol 2006; 55: 449-59.
27. Mimouni D, Anhalt GJ, Cummins DL et al. Treatment of pemphigus vulgaris and pemphigus foliaceus with mycophenolate mofetil. Arch Dermatol 2003; 139: 739-42.
28. Sarma N, Ghosh S. Mycophenolate mofetil as adjuvant in pemphigus vulgaris. Indian J Dermatol Venereol Leprol 2007; 73: 348-50.
29. Sorce M, Arico M, Bongiorno MR. Rituximab in refractory pemphigus vulgaris. Dermatol Ther 2008; 21 Suppl 1: S6-9.